✦ LIBER ✦

A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-α, in patients with corticosteroid-dependent Crohn's disease

✍ Scribed by B. G. Feagan; W. J. Sandborn; J. P. Baker; F. Cominelli; L. R. Sutherland; C. O. Elson; B. A. Salzberg; A. Archambault; C. N. Bernstein; G. R. Lichtenstein; P. K. Heath; S. Cameron; S. B. Hanauer

Book ID: 108603962
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 331 KB
Volume: 21
Category: Article
ISSN: 0269-2813
DOI: 10.1111/j.1365-2036.2005.02336.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I, double-blind, randomized, place

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease

✍ C. Janneke van der Woude; Pieter Stokkers; Ad A. van Bodegraven; Gert Van Assche 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB 👁 2 views

Background: NI-0401 is a fully human monoclonal antibody, which binds to the CD3 subunit of the T-cell receptor, causing modulation of T-cell activity. We investigated the safety and the ability to modulate the TCR-CD3 complex of NI-0401 in patients with active Crohn's disease (CD). Methods: A doub

Assessment of antibodies to double-stran

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: Findings in open-label and randomized placebo-controlled trials

✍ P. J. Charles; R. J. T. Smeenk; J. De Jong; M. Feldmann; R. N. Maini 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 2 views

Objective. To compare the incidence of antidouble-stranded DNA (anti-dsDNA) antibodies in rheumatoid arthritis (RA) patients receiving either single or multiple doses of a chimeric anti-tumor necrosis factor ␣ (anti-TNF␣) antibody or placebo infusions, with or without methotrexate, in open-label, ra

Golimumab, a new human anti–tumor necros

Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight–week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

✍ Joel Kremer; Christopher Ritchlin; Alan Mendelsohn; Daniel Baker; Lilianne Kim; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 282 KB 👁 1 views

Erratum: Golimumab, a new human anti–tum

Erratum: Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight–week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

✍ Joel Kremer; Christopher Ritchlin; Alan Mendelsohn; Daniel Baker; Lilianne Kim; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 40 KB 👁 1 views

Safety and efficacy of ocrelizumab in pa

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial

✍ P. P. Tak; P. J. Mease; M. C. Genovese; J. Kremer; B. Haraoui; Y. Tanaka; C. O. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views

Golimumab, a human anti–tumor necrosis f

Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four–week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

✍ Paul Emery; Roy M. Fleischmann; Larry W. Moreland; Elizabeth C. Hsia; Ingrid Str 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views